Sol-Gel Technologies (NASDAQ:SLGL) Given New $50.00 Price Target at HC Wainwright

Sol-Gel Technologies (NASDAQ:SLGL) had its target price increased by HC Wainwright from $6.00 to $50.00 in a research note published on Monday morning, MarketBeat.com reports. The firm currently has a buy rating on the stock.

A number of other equities research analysts also recently issued reports on the stock. Wall Street Zen upgraded shares of Sol-Gel Technologies to a “buy” rating in a research note on Saturday, September 13th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Sol-Gel Technologies in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

Sol-Gel Technologies Stock Up 2.1%

Shares of Sol-Gel Technologies stock opened at $39.81 on Monday. The company has a market capitalization of $110.91 million, a price-to-earnings ratio of -32.37 and a beta of 1.29. Sol-Gel Technologies has a 12-month low of $4.01 and a 12-month high of $52.26. The firm’s 50-day moving average price is $30.30 and its two-hundred day moving average price is $16.14.

Sol-Gel Technologies (NASDAQ:SLGL) last announced its quarterly earnings data on Friday, August 15th. The company reported $4.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $4.84. The firm had revenue of $17.26 million for the quarter, compared to the consensus estimate of $2.86 million. Sol-Gel Technologies had a negative net margin of 14.25% and a negative return on equity of 11.80%. On average, sell-side analysts expect that Sol-Gel Technologies will post -0.28 earnings per share for the current year.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.